BridgeBio Pharma BBIO
NASDAQ BBIO
$79.54 +0.87 (+1.11%)
At close: Nov 11, 2026 · 4:00 PM EST

BridgeBio Pharma (BBIO) Short-Term Debt repayments (2025)

Updated

BridgeBio Pharma (BBIO) reported Short-Term Debt repayments of $459 million for FY2025, down 3.0% from $473.42 million in FY2024.

Analysis

BridgeBio Pharma (BBIO) Short-Term Debt repayments (2025) Analysis & Trends

  • According to Business Quant data, Short-Term Debt repayments came in at $473.42 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ST Debt Repayment (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 6.63 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 BridgeBio Pharma 15.42 Bn 11.64 Bn 332.72 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 459.00 Mn
API Access

BridgeBio Pharma Short-Term Debt repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt-repayments&ticker=BBIO&period=max&api_key=YOUR_API_KEY